article thumbnail

STAT+: Oncologists more likely to provide low-value care after receiving pharma money, study finds

STAT

The other scenario involved treatments that were more expensive, but no more effective than alternatives, such as the Abraxane chemotherapy. The researchers examined Medicare beneficiaries who were diagnosed with cancer and received treatment from 2014 through 2019.

article thumbnail

EHA: Survival data sets Daiichi Sankyo’s quizartinib back on track

pharmaphorum

Data from the QuANTUM-First trial presented at the EHA congress showed that quizartinib more than doubled the median overall survival when added to first-line chemotherapy in patients with newly-diagnosed, FLT3-ITD-positive acute myeloid leukaemia (AML). Quizartinib plus standard chemotherapy reduced the risk of death by 22.4%

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

2022 IDstewardship Year End Review

IDStewardship

As someone who enjoys the simplicity of Sesame Street and the complexity of Antimicrobial Chemotherapy, this one was near and dear to my heart as well as a long time coming. July 2014 – IDstewardship Facebook page created. July 2014 – IDstewardship Pinterest account created. April 2014 – @IDstewardship first post to Instagram.

article thumbnail

Failed trial nixes another FDA approval, this time for BMS’ Istodax

pharmaphorum

The HDAC inhibitor was given an accelerated approval by the FDA as a second-line PTCL therapy on the strength of overall response data, but a phase 3 study comparing Istodax to first-line chemotherapy showed no improvement on progression-free survival (PFS).

FDA 98
article thumbnail

Novel oral chemotherapeutic holds potential for stomach cancer patients

European Pharmaceutical Review

The availability of oral chemotherapy treatments would provide stomach cancer patients with the option of more efficacious drugs with improved tolerability in a more convenient dosage format” The poor clinical outcomes of stomach cancer make it a key target for drug development. Benefits of daily oral chemotherapy over IV.

article thumbnail

NICE says no to AZ’s Lynparza for prostate cancer

pharmaphorum

AZ is seeking to use Lynparza in patients who had also been previously treated with the chemotherapy drug docetaxel, but NICE has concluded that the application failed to provide evidence of the PARP inhibitor’s value compared to standard therapy.

article thumbnail

AZ aims at Pfizer, GSK with potential new PARP cancer drug

pharmaphorum

AstraZeneca’s Lynparza (olaparib) blazed a trail for the new class of PARP drugs when it was approved in 2014 to treat ovarian cancer. . There was a real reason to think that dialling out PARP2 might make PARP inhibitors better tolerated both as monotherapy and in combination with chemotherapy,” he said.